Effects of new generation triptans – frovatriptan and almotriptan – on hemodynamic parameters in intact male and female rats

Saracheva, Kremena; Hrischev, Petar; Vasileva, Liliya; Topolov, Mariyan; Nikolova, Julia; Getova, Damianka

doi:10.2478/acph-2020-0005

Abstract

The introduction of the second generation triptans in clinical and experimental practice was a major progress in the pharmacotherapy of migraine. Frovatriptan is a second generation triptan with strong 5-HT_1B/1D serotonergic agonism and low 5-HT_1A/7 receptor affinity, while almotriptan possesses not only the typical 5-HT_1B/1D receptor agonist activity, but shows an affinity to the 5-HT_1F receptor. The aim of our study was to assess the impact of frovatriptan and almotriptan on hemodynamics in male and female rats. We used a non-invasive “tail-cuff” method to measure the arterial blood pressure. Female and male Wistar rats were treated separately with high and low dosages of frovatriptan and almotriptan. Male and female rats showed reduction in all hemodynamic parameters, but only male rats showed an increase in the heart rate. In general, we could say that both almotriptan and frovatriptan potentiate cardiovascular safety.

References

1. G. Mancia, E. A. Rosei, E. Ambrosioni, F. Avino, A. Carolei, M. Daccò, G. Di Giacomo, C. Ferri, I. Grazioli, G. Melzi, G. Nappi, L. Pinessi, G. Sandrini, B. Trimarco and G. Zanchin, MIRACLES Study Group. Hypertension and migraine comorbidity: prevalence and risk of cerebrovascular events: evidence from a large, multicenter, cross-sectional survey in Italy (MIRACLES study), J. Hypertens.29 (2011) 309–318; https://doi.org/10.1097/HJH.0b013e328341040410.1097/HJH.0b013e3283410404
Search in Google Scholar Back to article
2. E. P. Widmeier, H. Raff and K. T. Strang, Vander’s Human Physiology: The Mechanisms of Body Function, 13th ed., McGraw-Hill, New York 2014 pp. 408–413.
Search in Google Scholar Back to article
3. S. W. Watts, S. F. Morrison, R. P. Davis and S. M. Barman, Serotonin and blood pressure regulation, Pharmacol. Rev.64 (2012) 359–388; https://doi.org/10.1124/pr.111.00469710.1124/pr.111.004697
Search in Google Scholar Back to article
4. F. Côté, C. Fligny, Y. Fromes, J. Mallet and G. Vodjdani, Recent advances in understanding serotonin regulation of cardiovascular function, Trends Mol. Med.10 (2004) 232–238; https://doi.org/10.1016/j.molmed.2004.03.00710.1016/j.molmed.2004.03.007
Search in Google Scholar Back to article
5. D. W. Dodick and V. Papademetriou, Cardiovascular safety of triptans, Cephalalgia24 (2004) 513–514; https://journals.sagepub.com/doi/10.1111/j.1468-2982.2003.00714.x10.1111/j.1468-2982.2003.00714.x
Search in Google Scholar Back to article
6. V. Tullo, G. Bussone, S. Omboni, P. Barbanti, P. Cortelli, M. Curone, C. Peccarisi, C. Benedetto, D. Pezzola, D. Zava and G. Allais, Efficacy of frovatriptan and other triptans in the treatment of acute migraine of hypertensive and normotensive subjects: a review of randomized studies, Neurol. Sci.34 (2013) 87–91; https://doi.org/10.1007/s10072-013-1367-z10.1007/s10072-013-1367-z
Search in Google Scholar Back to article
7. S. Watts and R. Davis, 5-Hydroxtryptamine receptors in systemic hypertension: an arterial focus, Cardiovasc. Ther.29 (2011) 54–67; https://doi.org/10.1111/j.1755-5922.2010.00173.x10.1111/j.1755-5922.2010.00173.x
Search in Google Scholar Back to article
8. M. Reboredo, H. C. Y. Chang, R. Barbero, C. M. Rodríguez-Ortigosa, F. Pérez-Vizcaíno, A. Morán, M. García, J. M. Banales, N. Carreño, F. Alegre, I. Herrero, J. Quiroga, J. Prieto and B. Sangro, Zolmitriptan: a novel portal hypertensive agent which synergizes with propranolol in lowering portal pressure, PLoS ONE8 (2013) e52683 (9 pages); https://doi.org/10.1371/journal.pone.005268310.1371/journal.pone.0052683
Search in Google Scholar Back to article
9. T. Gori, J. S. Floras and J. D. Parker, Effects of nitroglycerin treatment on baroreflex sensitivity and short-term heart rate variability in humans, J. Am. Coll. Cardiol.40 (2002) 2000–2005; https://doi.org/10.1016/S0735-1097(02)02532-910.1016/S0735-1097(02)02532-9
Search in Google Scholar Back to article
10. A. Negro, L. Lionetto, B. Casolla, N. Lala, M. Simmaco and P. Martelletti, Pharmacokinetic evaluation of frovatriptan, Expert Opin. Drug Metab. Toxicol.7 (2011) 1449–1458; https://doi.org/10.1517/17425255.2011.62226510.1517/17425255.2011.62226521929465
Search in Google Scholar Back to article
11. A. Matthys, G. Haegeman, K. Van Craenenbroeck and P. Vanhoenacker, Role of the 5-HT7 receptor in the central nervous system: from current status to future perspectives, Mol. Neurobiol.43 (2011) 228–253; https://doi.org/10.1007/s12035-011-8175-310.1007/s12035-011-8175-321424680
Search in Google Scholar Back to article
12. D. Guseva, A. Wirth and E. Ponimaskin, Cellular mechanisms of the 5-HT7 receptor-mediated signaling, Front. Behav. Neurosci.8 (2014) Article ID 306 (8 pages); https://doi.org/10.3389/fnbeh.2014.0030610.3389/fnbeh.2014.00306
Search in Google Scholar Back to article
13. M. B. Comer, Pharmacology of the selective 5-HT1B/1D agonist frovatriptan, Headache42 (2002) 47–53; https://doi.org/10.1046/j.1526-4610.42.s2.2.x10.1046/j.1526-4610.42.s2.2.x
Search in Google Scholar Back to article
14. J. Gras, J. Llenas, J. M. Jansat, J. Jáuregui, X. Cabarrocas and J. M. Palacios, Almotriptan, a new anti-migraine agent: a review, CNS Drug Rev.8 (2002) 217–234; https://doi.org/10.1111/j.1527-3458.2002.tb00226.x10.1111/j.1527-3458.2002.tb00226.x
Search in Google Scholar Back to article
15. A. G. Ramage, Central cardiovascular regulation and 5-hydroxytryptamine receptors, Brain Res.Bull.56 (2001) 425–439; https://doi.org/10.1016/S0361-9230(01)00612-810.1016/S0361-9230(01)00612-8
Search in Google Scholar Back to article
16. M. Van den Buuse and N. Wegener, Involvement of serotonin1A receptors in cardiovascular responses to stress: a radio-telemetry study in four rat strains, Eur. J. Pharmacol.507 (2005) 187–198; https://doi.org/10.1016/j.ejphar.2004.11.04810.1016/j.ejphar.2004.11.04815659309
Search in Google Scholar Back to article
17. F. Pagniez, J. P. Valentin, S. Vieu, F. C. Colpaert and G. W. John, Pharmacological analysis of the haemodynamic effects of 5-HT1B/D receptor agonists in the normotensive rat, Br. J. Pharmacol.123 (1998) 205–214; https://doi.org/10.1038/sj.bjp.070159310.1038/sj.bjp.070159315651559489607
Search in Google Scholar Back to article

Effects of new generation triptans – frovatriptan and almotriptan – on hemodynamic parameters in intact male and female rats

Abstract

Paradigm

My account